Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling - PubMed
8 hours ago
- #STING Pathway
- #Anti-PD-1 Therapy
- #Oncolytic Immunotherapy
- RP1 (vusolimogene oderparepvec) is an oncolytic herpes simplex virus used in immunotherapy.
- RP1 replication occurs in tumor cells but not in splenocytes.
- RP1 induces an interferon response in splenocytes via STING, transmitted to tumor cells non-touch-dependently.
- Tumor cells respond by upregulating MHC-I and PD-L1 via JAK-STAT signaling.
- In vivo, RP1 injection increases IFN signature in both injected and non-injected tumors, enhanced with anti-PD-1 therapy.
- RP1 recruits PD-L1+ CD11b+Ly6G+ neutrophils into the tumor microenvironment.
- RP1 remodels the tumor microenvironment, creating a more inflamed phenotype.